Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.86 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.86 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.86 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082224 | 0.92 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL18268431 | 0.90 | GUCY1B2 (0.86) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082048 | 0.90 | GUCY1B2 (0.86) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082036 | 0.89 | GUCY1B2 (0.84) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082038 | 0.89 | GUCY1B2 (0.83) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL29831392 | 0.88 | GUCY1B2 (0.77) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3439239 | 0.88 | GUCY1B2 (0.77) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082603 | 0.88 | GUCY1B2 (0.82) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16081819 | 0.86 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15087567 | 0.86 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200316065-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3660013-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190167679-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10183021-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170136019-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2015106268-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | SMN1; SMN2, PRKG1, GUCY1A2 | GUCY1B2 8/4885GUCY1A2 3/4885GUCY1A1 6/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-20160347738-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-10183021-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-20170136019-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-20190167679-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
| US-20200316065-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.